[News Brief] Everest Medicines Licenses Kidney Disease Therapy to Travere
China-based Everest Medicines has entered an exclusive licensing and collaboration agreement with US-based Travere Therapeutics for the development and commercialisation…
Press Release
[News Brief] Daewoong Pharma Partners for Dupilumab Biosimilar Development
South Korea-based Daewoong Pharmaceutical has partnered with China-based Chime Biologics to develop and manufacture a dupilumab biosimilar candidate referencing Dupixent.…
[News Brief] FDA Approves Tremfya Label Expansion for Psoriatic Arthritis
The US Food and Drug Administration (FDA) has approved a label expansion for Tremfya (guselkumab) to include evidence for inhibition…
[News Brief] Pfizer Receives FDA Approval for Expanded Hympavzi Use
Pfizer has received US Food and Drug Administration (FDA) approval for an expanded indication of Hympavzi (marstacimab-hncq) for adults and…
[News Brief] Everest Medicines Licences Sumecigrel for Asia-Pacific Development
Everest Medicines has entered into an exclusive licensing agreement with Jiangsu Vcare PharmaTech Co. for the development, registration and commercialisation…
[News Brief] PharmaEssentia Receives Taiwan Approval for Besremi in ET
PharmaEssentia Corporation has received approval from Taiwan’s Ministry of Health and Welfare for Besremi (ropeginterferon alfa-2b) for the treatment of…
[News Brief] Formosa Pharma Signs Licensing Deal With Samil Pharmaceutical
Formosa Pharmaceuticals, Inc. has entered into an exclusive licensing agreement with Samil Pharmaceutical Co., Ltd. for the commercialisation of an…
[News Brief] Simcere Pharma Enters Research Collaboration With Stanford Medicine
Simcere Pharmaceutical Group Limited has entered a research collaboration with Stanford University School of Medicine to develop potential treatments for…
[News Brief] Zhenjiankang Medical Passes Hong Kong Listing Hearing
Guangdong Zhenjiankang Medical Technology Development Co., Ltd. has passed the Hong Kong Stock Exchange Main Board listing hearing under Chapter…
[News Brief] Metis TechBio Raises HK$2.1 Billion Through Hong Kong IPO
Metis TechBio Co Ltd has completed an initial public offering in Hong Kong, raising more than HK$2.1 billion to support…